US companies Amgen, Bristol Myers Squibb, Gilead Sciences, and Merck/MSD have signed up to reduce the prices of medicines for Medicare and cash buyers through the TrumpRx direct-to-consumer (DTC) ...

In 2025, women’s health moved from recognition to getting foundations in place, with new funding vehicles, national ...

While everyone agrees on the ethical imperative to reduce animal use, the challenge of widespread readiness will depend on partnership, proof, and continued development activities. Public perception ...

Combined, the two drugs made revenues of nearly $600 million in the last four quarters, while BioMarin has forecast that its ...

For much of the past year, the UK’s medicines pricing debate has cast a long shadow over the life sciences sector. The deadlock over NHS rebates – and the uncertainty surrounding the successor to VPAG ...

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist Sidekick and pharma ...

Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' companies originally ...

Pierre A. Morgon, PharmD, LL.M, MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease ...

The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug in the class ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ...

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.